Karyopharm announces updated exploratory subgroup analysis from siendo study in patients with advanced or recurrent tp53 wild-type endometrial cancer to be presented at asco plenary series on july 25th

-  data provide further support for company's ongoing phase 3 study evaluating selinexor as maintenance therapy following systemic therapy in patients with advanced or recurrent tp53 wild-type endometrial cancer - newton, mass. , july 19, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an updated exploratory subgroup analysis from the siendo study (nct03555422) in patients with advanced or recurrent tp53 wild-type endometrial cancer will be presented at the virtual american society of clinical oncology (asco) plenary series.
KPTI Ratings Summary
KPTI Quant Ranking